Timothy M. Caldwell - Concepedia

Author

Timothy M. Caldwell

Also Known As

Caldwell, Timothy M., T M Caldwell, T. M. CALDWELL, T. M. Caldwell, T.M. Caldwell, Timothy Caldwell, Timothy M Caldwell, Timothy M. Caldwell

Publications

Citations

H-Index

Concepts

All Affiliations

University of Kansas Northwestern University Deciphera Pharmaceuticals (United States)Oregon Health & Science University

About

Timothy M. Caldwell is an author at University of Kansas specializing in medicine, pharmacology, and drug discovery.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	8	570
2	Engineering	6	6	159
3	Biochemistry	6	6	145
4	Natural Sciences	5	5	107
5	Cell Biology	3	3	193

Timothy M. Caldwell

Publications

975

Citations

H-Index

Page 1

	Year	Citations
Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants Bryan D. Smith, Michael D. Kaufman, Wei-Ping Lu, Cancer Cell Pdgfra VariantsOncogenic AgentMedicineDrug-resistant KitReceptor Tyrosine Kinase	2019	270
Discovery of 1-(3,3-Dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-<i>d</i>]pyrimidin-6-yl)phenyl)urea (LY3009120) as a Pan-RAF Inhibitor with Minimal Paradoxical Activation and Activity against <i>BRAF</i> or <i>RAS</i> Mutant Tumor Cells James R. Henry, Michael D. Kaufman, Sheng-Bin Peng, Journal of Medicinal Chemistry Kinase InhibitorsPharmaceutical ChemistryTumor BiologyMolecular PharmacologyMedicinal Chemistry	2015	84
Altiratinib Inhibits Tumor Growth, Invasion, Angiogenesis, and Microenvironment-Mediated Drug Resistance via Balanced Inhibition of MET, TIE2, and VEGFR2 Bryan D. Smith, Michael D. Kaufman, Cynthia B. Leary, Molecular Cancer Therapeutics Switch Control PocketGliomaTumor BiologyAngiogenesisTumor Initiation	2015	75
Switching mode generation and optimal estimation with application to skid-steering Timothy M. Caldwell, Todd D. Murphey Automatica Motion ControlTrajectory PlanningEngineeringVehicle ControlGuidance System	2010	67
Vimseltinib: A Precision CSF1R Therapy for Tenosynovial Giant Cell Tumors and Diseases Promoted by Macrophages Bryan D. Smith, Michael D. Kaufman, Scott Wise, Molecular Cancer Therapeutics	2021	65
Synthesis and Biochemical Evaluation of 3-Fluoromethyl-1,2,3,4-tetrahydroisoquinolines as Selective Inhibitors of Phenylethanolamine <i>N</i>-Methyltransferase versus the α<sub>2</sub>-Adrenoceptor Gary L. Grunewald, Timothy M. Caldwell, Qifang Li, Journal of Medicinal Chemistry	1999	44
CRHR1 Receptor binding and lipophilicity of pyrrolopyrimidines, potential nonpeptide corticotropin-releasing hormone type 1 receptor antagonists Ling‐Wei Hsin, Xinrong Tian, Elizabeth Webster, Bioorganic & Medicinal Chemistry Molecular PhysiologyBiochemistryG Protein-coupled ReceptorMedicinePhysiology	2002	38
Discovery of Novel 6,6-Heterocycles as Transient Receptor Potential Vanilloid (TRPV1) Antagonists Charles A. Blum, Timothy M. Caldwell, Xiaozhang Zheng, Journal of Medicinal Chemistry Chronic Inflammatory PainPain MedicineNeuropathic PainMolecular PainPharmacotherapy	2010	37
Synthesis and Evaluation of 3-Trifluoromethyl-7-substituted- 1,2,3,4-tetrahydroisoquinolines as Selective Inhibitors of Phenylethanolamine<i>N</i>-Methyltransferase versus the α<sub>2</sub>-Adrenoceptor Gary L. Grunewald, Timothy M. Caldwell, Qifang Li, Journal of Medicinal Chemistry	1999	35
Discovery of vimseltinib (DCC-3014), a highly selective CSF1R switch-control kinase inhibitor, in clinical development for the treatment of Tenosynovial Giant Cell Tumor (TGCT) Timothy M. Caldwell, Yu Mi Ahn, Stacie L. Bulfer, Bioorganic & Medicinal Chemistry Letters ImmunologyExquisite SelectivityTumor BiologyMedicinal ChemistryLead Compound 3	2022	34

Page 1